Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer

Por Cole, Claire, Lau, Sin, Backen, Alison, Clamp, Andrew, Rushton, Graham, Dive, Caroline, Hodgkinson, Cassandra, McVey, Rhona, Kitchener, Henry, Jayson, Gordon C
Publicado em 2010

The combination of circulating Ang1 and Tie2 levels predict progression free survival advantage in Bevacizumab-treated ovarian cancer patients

Por Backen, Alison, Renehan, Andrew G., Clamp, Andrew R., Berzuini, Carlo, Zhou, Cong, Oza, Amit, Bannoo, Selina, Scherer, Stefan J., Banks, Rosamonde E., Dive, Caroline, Jayson, Gordon C.
Publicado em 2014

Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab

Por Zhou, Cong, Clamp, Andrew, Backen, Alison, Berzuini, Carlo, Renehan, Andrew, Banks, Rosamonde E, Kaplan, Richard, Scherer, Stefan J, Kristensen, Gunnar B, Pujade-Lauraine, Eric, Dive, Caroline, Jayson, Gordon C
Publicado no Br J Cancer (2016)

Discovery and Validation of Predictive Biomarkers of Survival for Non-small Cell Lung Cancer Patients Undergoing Radical Radiotherapy: Two Proteins With Predictive Value

Por Walker, Michael J., Zhou, Cong, Backen, Alison, Pernemalm, Maria, Williamson, Andrew J.K., Priest, Lynsey J.C., Koh, Pek, Faivre-Finn, Corinne, Blackhall, Fiona H., Dive, Caroline, Whetton, Anthony D.
Publicado no EBioMedicine (2015)

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

Por Valle, Juan W, Wasan, Harpreet, Lopes, Andre, Backen, Alison C, Palmer, Daniel H, Morris, Karen, Duggan, Marian, Cunningham, David, Anthoney, D Alan, Corrie, Pippa, Madhusudan, Srinivasan, Maraveyas, Anthony, Ross, Paul J, Waters, Justin S, Steward, Will P, Rees, Charlotte, Beare, Sandy, Dive, Caroline, Bridgewater, John A
Publicado no Lancet Oncol (2015)